• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多中心蛋白质组学全基因组孟德尔随机化研究鉴定黑色素瘤和非黑色素瘤皮肤癌中的因果性血浆蛋白。

Multicenter proteome-wide Mendelian randomization study identifies causal plasma proteins in melanoma and non-melanoma skin cancers.

机构信息

Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.

National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.

出版信息

Commun Biol. 2024 Jul 13;7(1):857. doi: 10.1038/s42003-024-06538-2.

DOI:10.1038/s42003-024-06538-2
PMID:39003418
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11246481/
Abstract

This study addresses the diagnostic and therapeutic challenges in malignant melanoma (MM) and non-melanoma skin cancers (NMSC). We aim to identify circulating proteins causally linked to MM and NMSC traits using a multicenter Mendelian randomization (MR) framework. We utilized large-scale cis-MR to estimate the impact of numerous plasma proteins on MM, NMSC, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC). To ensure robustness, additional analyses like MR Steiger and Bayesian colocalization are conducted, followed by replication through meta-analytical methods. The associations between identified proteins and outcomes are also validated at the tissue level using Transcriptome-Wide Association Study methods. Furthermore, a protein-protein interaction analysis is conducted to explore the relationship between identified proteins and existing cancer medication targets. The MR analysis has identified associations of 13 plasma proteins with BCC, 2 with SCC, and 1 with MM. Specifically, ASIP and KRT5 are associated with BCC, with ASIP also potentially targeting MM. CTSS and TNFSF8 are identified as promising druggability candidates for BCC. This multidimensional approach nominates ASIP, KRT5, CTSS, and TNFSF8 as potential diagnostic and therapeutic targets for skin cancers.

摘要

本研究针对恶性黑色素瘤(MM)和非黑色素瘤皮肤癌(NMSC)的诊断和治疗挑战。我们旨在使用多中心孟德尔随机化(MR)框架,确定与 MM 和 NMSC 特征相关的循环蛋白。我们利用大规模顺式-MR 来估计众多血浆蛋白对 MM、NMSC、鳞状细胞癌(SCC)和基底细胞癌(BCC)的影响。为了确保稳健性,还进行了 MR Steiger 和贝叶斯共定位等额外分析,并通过荟萃分析方法进行复制。还使用转录组关联研究方法在组织水平上验证了鉴定出的蛋白质与结果之间的关联。此外,还进行了蛋白质-蛋白质相互作用分析,以探索鉴定出的蛋白质与现有癌症药物靶点之间的关系。MR 分析确定了 13 种血浆蛋白与 BCC、2 种与 SCC 和 1 种与 MM 相关。具体来说,ASIP 和 KRT5 与 BCC 相关,ASIP 也可能针对 MM。CTSS 和 TNFSF8 被确定为 BCC 的有希望的药物靶点候选物。这种多维方法将 ASIP、KRT5、CTSS 和 TNFSF8 提名作为皮肤癌的潜在诊断和治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f386/11246481/a06812d0d05a/42003_2024_6538_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f386/11246481/fd5c69435ab4/42003_2024_6538_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f386/11246481/3ef1583397c8/42003_2024_6538_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f386/11246481/1a57c62d6c40/42003_2024_6538_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f386/11246481/a06812d0d05a/42003_2024_6538_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f386/11246481/fd5c69435ab4/42003_2024_6538_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f386/11246481/3ef1583397c8/42003_2024_6538_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f386/11246481/1a57c62d6c40/42003_2024_6538_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f386/11246481/a06812d0d05a/42003_2024_6538_Fig4_HTML.jpg

相似文献

1
Multicenter proteome-wide Mendelian randomization study identifies causal plasma proteins in melanoma and non-melanoma skin cancers.多中心蛋白质组学全基因组孟德尔随机化研究鉴定黑色素瘤和非黑色素瘤皮肤癌中的因果性血浆蛋白。
Commun Biol. 2024 Jul 13;7(1):857. doi: 10.1038/s42003-024-06538-2.
2
Systematic proteome-wide Mendelian randomization to prioritize causal plasma proteins for skin cancers.全蛋白质组范围的系统孟德尔随机化研究,以确定皮肤癌的因果性血浆蛋白优先级。
Commun Biol. 2024 Dec 19;7(1):1681. doi: 10.1038/s42003-024-07403-y.
3
Identification of plasma protein markers of allergic disease risk: a mendelian randomization approach to proteomic analysis.鉴定过敏疾病风险的血浆蛋白标志物:蛋白质组分析的孟德尔随机化方法。
BMC Genomics. 2024 May 22;25(1):503. doi: 10.1186/s12864-024-10412-0.
4
Identification of potential drug targets for four site-specific cancers by integrating human plasma proteome with genome.通过整合人类血浆蛋白质组与基因组来鉴定四种特定部位癌症的潜在药物靶点。
J Pharm Biomed Anal. 2025 Jun 15;258:116731. doi: 10.1016/j.jpba.2025.116731. Epub 2025 Feb 6.
5
Genetically predicted TWEAK mediates the association between lipidome and Keratinocyte Carcinomas.遗传预测的 TWEAK 介导脂质组学与角化细胞癌之间的关联。
Skin Res Technol. 2024 Jul;30(7):e13781. doi: 10.1111/srt.13781.
6
Evaluating the causal effect of circulating proteome on the risk of inflammatory bowel disease-related traits using Mendelian randomization.采用孟德尔随机化方法评估循环蛋白质组对炎症性肠病相关特征风险的因果效应。
Front Immunol. 2024 Jul 31;15:1434369. doi: 10.3389/fimmu.2024.1434369. eCollection 2024.
7
PTGES2 and RNASET2 identified as novel potential biomarkers and therapeutic targets for basal cell carcinoma: insights from proteome-wide mendelian randomization, colocalization, and MR-PheWAS analyses.PTGES2和RNASET2被鉴定为基底细胞癌新的潜在生物标志物和治疗靶点:来自全蛋白质组孟德尔随机化、共定位和MR-PheWAS分析的见解
Front Pharmacol. 2024 Jul 5;15:1418560. doi: 10.3389/fphar.2024.1418560. eCollection 2024.
8
The causal relationship between immune cells mediating FIT3L, CCL4, OSM, and skin-derived deteriorated tumors.介导 FIT3L、CCL4、OSM 的免疫细胞与皮肤来源恶化肿瘤之间的因果关系。
Skin Res Technol. 2024 Jul;30(7):e13774. doi: 10.1111/srt.13774.
9
Can alterations in cathepsin levels restrain the development of skin cancer?: A bidirectional multivariate Mendelian-randomization study.组织蛋白酶水平的改变能否抑制皮肤癌的发展?:一项双向多变量孟德尔随机化研究。
Medicine (Baltimore). 2024 Sep 20;103(38):e39628. doi: 10.1097/MD.0000000000039628.
10
Causal relationship between the gut microbiome and basal cell carcinoma, melanoma skin cancer, ease of skin tanning: evidence from three two-sample mendelian randomisation studies.肠道微生物组与基底细胞癌、黑色素瘤皮肤癌、皮肤晒黑难易程度的因果关系:来自三项两样本孟德尔随机化研究的证据。
Front Immunol. 2024 Jan 18;15:1279680. doi: 10.3389/fimmu.2024.1279680. eCollection 2024.

引用本文的文献

1
SPAG11B, a potential biomarker for rheumatoid arthritis: a two-sample bidirectional Mendelian randomization analysis.SPAG11B,类风湿性关节炎的一种潜在生物标志物:一项两样本双向孟德尔随机化分析
BMC Rheumatol. 2025 Jun 4;9(1):65. doi: 10.1186/s41927-025-00521-y.
2
Genetic Analysis Reveals a Protective Effect of Sphingomyelin on Cholelithiasis.基因分析揭示鞘磷脂对胆结石的保护作用。
Genes (Basel). 2025 Apr 29;16(5):523. doi: 10.3390/genes16050523.
3
Integrating analysis of multi-omics summary data identifies novel plasma protein biomarkers and drug targets for bladder cancer.

本文引用的文献

1
Bromodomain inhibition targeting BPTF in the treatment of melanoma and other solid tumors.靶向 BPTF 的溴结构域抑制在黑色素瘤和其他实体瘤治疗中的应用。
Clin Exp Metastasis. 2024 Aug;41(4):509-515. doi: 10.1007/s10585-024-10265-7. Epub 2024 Apr 29.
2
Current State of Melanoma Therapy and Next Steps: Battling Therapeutic Resistance.黑色素瘤治疗的现状与后续步骤:对抗治疗耐药性
Cancers (Basel). 2024 Apr 19;16(8):1571. doi: 10.3390/cancers16081571.
3
Vitamin D and Cutaneous Melanoma Risk: An Umbrella Review of Systematic Reviews and Meta-Analyses.
多组学汇总数据的整合分析鉴定出膀胱癌新的血浆蛋白生物标志物和药物靶点。
Discov Oncol. 2025 May 2;16(1):660. doi: 10.1007/s12672-025-02476-5.
维生素 D 与皮肤黑色素瘤风险:系统评价和荟萃分析的伞状综述。
Photobiomodul Photomed Laser Surg. 2024 Apr;42(4):249-266. doi: 10.1089/photob.2023.0175.
4
Brentuximab vedotin for skin involvement in refractory diffuse cutaneous systemic sclerosis, an open-label trial.用于难治性弥漫性皮肤系统性硬化症皮肤受累的本妥昔单抗,一项开放标签试验。
Rheumatology (Oxford). 2025 Mar 1;64(3):1476-1481. doi: 10.1093/rheumatology/keae235.
5
Deciphering and overcoming Anti-PD-1 resistance in Melanoma: A comprehensive review of Mechanisms, biomarker Developments, and therapeutic strategies.解析并克服黑色素瘤的抗 PD-1 耐药性:机制、生物标志物开发和治疗策略的全面综述。
Int Immunopharmacol. 2024 May 10;132:111989. doi: 10.1016/j.intimp.2024.111989. Epub 2024 Apr 8.
6
A Comprehensive Review of Various Therapeutic Strategies for the Management of Skin Cancer.皮肤癌治疗策略的综合综述
ACS Omega. 2024 Feb 22;9(9):10030-10048. doi: 10.1021/acsomega.3c09780. eCollection 2024 Mar 5.
7
Aggressive T-cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management.侵袭性 T 细胞淋巴瘤:2024 年:诊断、风险分层和治疗的更新。
Am J Hematol. 2024 Mar;99(3):439-456. doi: 10.1002/ajh.27165. Epub 2024 Feb 2.
8
Therapeutic Targets for Diabetic Kidney Disease: Proteome-Wide Mendelian Randomization and Colocalization Analyses.糖尿病肾病的治疗靶点:蛋白质组范围的孟德尔随机化和共定位分析。
Diabetes. 2024 Apr 1;73(4):618-627. doi: 10.2337/db23-0564.
9
Brentuximab vedotin in treating Chinese patients with lymphoma: A multicenter, real-world study.贝林妥欧单抗治疗中国淋巴瘤患者的多中心真实世界研究。
Cancer Med. 2023 Dec;12(24):21725-21734. doi: 10.1002/cam4.6733. Epub 2023 Nov 17.
10
Childhood sunburn and risk of melanoma and non-melanoma skin cancer: a Mendelian randomization study.儿童期晒伤与黑色素瘤和非黑色素瘤皮肤癌风险:一项孟德尔随机研究。
Environ Sci Pollut Res Int. 2023 Dec;30(58):122011-122023. doi: 10.1007/s11356-023-30535-3. Epub 2023 Nov 14.